Ultragenyx, a biopharmaceutical company dedicated to developing innovative medicines for rare and ultrarare diseases, has secured $75.0 million in funding. This investment will support the company's ongoing mission to address significant unmet medical needs. Founded in 2010, Ultragenyx has rapidly established itself by building a diverse portfolio of approved therapies and a robust clinical pipeline, specifically targeting debilitating genetic diseases that often lack any approved treatments.
The company's mission centers on delivering meaningful impact for patients and their families, both during the development and commercialization phases of its therapies. Ultragenyx emphasizes doing the right things for patients, driven by a commitment to courage, care, talent, and dedication. This approach is crucial in bringing novel products to those living with debilitating genetic diseases, many of which have no existing approved therapies.
This capital infusion is expected to significantly bolster Ultragenyx's ongoing growth initiatives and further its efforts in advancing its extensive clinical pipeline. The funding will enable the company to continue its critical work in discovering, developing, and commercializing therapies that can make a profound difference in the lives of individuals affected by rare diseases. Ultragenyx maintains a steadfast focus on expanding its reach and impact within the global rare disease community, ensuring more patients have access to potentially life-changing treatments.
Looking ahead, Ultragenyx plans to strategically leverage this investment to accelerate its research and development programs, ensuring the continued progression of its innovative medicines from discovery through to commercialization. The company remains deeply committed to its purpose of delivering transformative therapies and fostering an inclusive culture that empowers its team to effectively serve the rare disease community.
